AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29509892 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS) with resection of bullae/blebs and mechanical pleurodesis
Number of subjects: 181
Study 29509892 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest tube treatment
Number of subjects: 181
Study 29509892 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS) for bullae ≥1 cm
Number of subjects: 181
Study 29509892 — intervention group
Group type: EXPERIMENTAL
Intervention: Size-response relationship for bullae
Number of subjects: 181
Study 27912950 — intervention group
Group type: EXPERIMENTAL
Intervention: aYPFS plus montelukast
Number of subjects: 57
Study 27912950 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus montelukast
Number of subjects: 57
Study 24803369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexicalized conceptual metaphors
Number of subjects: 13
Study 24803369 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel conceptual metaphors
Number of subjects: 13
Study 24803369 — intervention group
Group type: COMPARATOR
Intervention: Typically developing (TD) controls
Number of subjects: 13
Study 22313550 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc by Bazett's formula (QTcB)
Number of subjects: 207
Study 22313550 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc by Fridericia's method (QTcF)
Number of subjects: 207
Study 22313550 — intervention group
Group type: EXPERIMENTAL
Intervention: Between‐subject variability in QTcF
Number of subjects: 207
Study 22313550 — intervention group
Group type: EXPERIMENTAL
Intervention: Within‐subject variability in QTcF
Number of subjects: 207
Study 20634469 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based add-on component (Raising Smoke-Free Kids)
Number of subjects: 1386
Study 20634469 — intervention group
Group type: COMPARATOR
Intervention: TNT-only condition (control)
Number of subjects: 1386
Study 19803312 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg of intravenous fentanyl
Number of subjects: 170
Study 19803312 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 170
Study 19803312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pretreatment
Number of subjects: 170
Study 15735462 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite with 17% EDTA for 1 min followed by 5-ml rinse with 5.25% NaOCl
Number of subjects: 73
Study 15735462 — intervention group
Group type: COMPARATOR
Intervention: 1.3% NaOCl with MTAD for 5 min
Number of subjects: 73
Study 12895193 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (3 mg kg(‐1))
Number of subjects: 48
Study 10026403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral (Neoral)
Number of subjects: 14
Study 10026403 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 14
Study 8901755 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus ICD
Number of subjects: 724
Study 8901755 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 724
Study 8901755 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients judged too unstable for randomization
Number of subjects: 724
Study 2005163 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist immobilisation in dorsiflexion
Number of subjects: 204
Study 2005163 — intervention group
Group type: COMPARATOR
Intervention: Wrist immobilisation in palmar flexion
Number of subjects: 204
Study 2005163 — intervention group
Group type: COMPARATOR
Intervention: Wrist immobilisation in neutral position
Number of subjects: 204
Study 6383760 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg X min)
Number of subjects: 25
Study 6383760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial single infusion)
Number of subjects: 25
Study 31389509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection (0.375% at doses of 2.5 ml in each belly of the anterior and middle scalene muscles, guided by ultrasonography)
Number of subjects: 38
Study 31389509 — intervention group
Group type: COMPARATOR
Intervention: Skin pressure in each belly of the anterior and middle scalene muscles (control group)
Number of subjects: 38
Study 27757595 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy nutritional intervention (30 g/day soy protein)
Number of subjects: 26
Study 27438111 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 579
Study 27438111 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 579
Study 27438111 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-124-3p levels
Number of subjects: 579
Study 25277170 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of the primary tumour followed by systemic therapy (fluoropyrimidine-based chemotherapy in combination with bevacizumab)
Number of subjects: 0
Study 25277170 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy only (fluoropyrimidine-based chemotherapy in combination with bevacizumab)
Number of subjects: 0
Study 23171166 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Change Counselling (BCC) intervention for glaucoma education
Number of subjects: 0
Study 23171166 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard education without BCC)
Number of subjects: 0
Study 20175609 — intervention group
Group type: EXPERIMENTAL
Intervention: Family focused treatment
Number of subjects: 58
Study 17370096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0
Study 17370096 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 17370096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 0
Study 15734713 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activity
Number of subjects: 13
Study 15734713 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity treatment designed to increase TEE by 7%
Number of subjects: 13
Study 15734713 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity treatment designed to increase TEE by 11%
Number of subjects: 13
Study 12392115 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg isometric exercise training for 5 weeks
Number of subjects: 27
Study 12392115 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm isometric exercise training for 5 weeks
Number of subjects: 27
Study 12392115 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 27
Study 10433672 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol gel sanitizer with antimicrobial lotion soap
Number of subjects: 0
Study 10433672 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol gel sanitizer with nonantimicrobial lotion soap
Number of subjects: 0
Study 10433672 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol gel sanitizer alone
Number of subjects: 0
Study 10433672 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial lotion soap alone
Number of subjects: 0
Study 10433672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonantimicrobial lotion soap alone
Number of subjects: 0
Study 7726774 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated night vision goggle (NVG) helmets
Number of subjects: 10
Study 2093235 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding first child
Number of subjects: 0
Study 2093235 — intervention group
Group type: COMPARATOR
Intervention: Not breastfeeding first child
Number of subjects: 0
Study 2093235 — intervention group
Group type: COMPARATOR
Intervention: Education beyond high school
Number of subjects: 0
Study 2093235 — intervention group
Group type: COMPARATOR
Intervention: Short duration or unsuccessful breastfeeding experience
Number of subjects: 0
Study 2093235 — intervention group
Group type: COMPARATOR
Intervention: Not having education beyond high school or receiving anesthesia at later birth
Number of subjects: 0
Study 215555 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (40-50 mg/kg/day)
Number of subjects: 3
Study 215555 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (25-30 mg/kg/day)
Number of subjects: 3
Study 215555 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (lower dosage)
Number of subjects: 3
Study 31439593 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (2 mg naloxone, max 8 mg/day)
Number of subjects: 20
Study 31439593 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (4 mg naloxone, max 16 mg/day)
Number of subjects: 20
Study 27604303 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and financial education training program (16 hours over 3 months)
Number of subjects: 1746
Study 27604303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no program implemented)
Number of subjects: 1746
Study 25074341 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Intervention: Telephone Tracking ‐ Caregiver (FITT‐C)
Number of subjects: 250
Study 25074341 — intervention group
Group type: COMPARATOR
Intervention: Telephone Support (TS)
Number of subjects: 250
Study 24428092 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% onion extract in silicone derivative gel
Number of subjects: 39
Study 24428092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22333169 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening psychological and behavioral intervention combined with varenicline
Number of subjects: 111
Study 22333169 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard intervention)
Number of subjects: 111
Study 22333169 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 111
Study 19249412 — intervention group
Group type: EXPERIMENTAL
Intervention: CVAR implementation model training for GPs
Number of subjects: 1320
Study 19249412 — intervention group
Group type: COMPARATOR
Intervention: Usual care by GPs
Number of subjects: 1320
Study 18038502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitaphenol Skin Cream (La Jolla Spa MD, La Jolla CA) applied to half of the face twice daily for 60 days
Number of subjects: 20
Study 18038502 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to half of the face twice daily for 60 days
Number of subjects: 20
Study 18038502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitaphenol Skin Cream
Number of subjects: 20
Study 18038502 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study 14742357 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight HES (HES 120; 20 mL/kg)
Number of subjects: 45
Study 14742357 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular-weight HES (HES 400; 20 mL/kg)
Number of subjects: 45
Study 14742357 — intervention group
Group type: COMPARATOR
Intervention: 4% human albumin (ALB)
Number of subjects: 45
Study 17062502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrant Med‐El Soundbridge (VSB) device implantation on the round window
Number of subjects: 7
Study 10670263 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 36
Study 10670263 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36
Study 8942302 — intervention group
Group type: EXPERIMENTAL
Intervention: Label group (child with ELD identified)
Number of subjects: 20
Study 8942302 — intervention group
Group type: COMPARATOR
Intervention: Nonlabel group (child with ELD not identified)
Number of subjects: 20
Study 1821972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of clomipramine at doses 75-300 mg daily for 7 to 16 days
Number of subjects: 28
Study 1821972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of maprotiline at doses 75-200 mg daily for 6 to 20 days
Number of subjects: 28
Study 1821972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both clomipramine and maprotiline
Number of subjects: 28
Study 7032378 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg/d methylprednisolone
Number of subjects: 46
Study 7032378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7032378 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta agonists
Number of subjects: 46
Study 31864822 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial FGF‐23 measurements and FGF‐23 trajectory group membership
Number of subjects: 1597
Study 31270970 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 140
Study 31270970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 30235727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanslim (high-dose)
Number of subjects: 165
Study 30235727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanslim (low-dose)
Number of subjects: 165
Study 30235727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 26685116 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced COPD
Number of subjects: 140
Study 26685116 — intervention group
Group type: COMPARATOR
Intervention: Advanced cancer
Number of subjects: 140
Study 24572581 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 60
Study 24572581 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study 22273590 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 40
Study 22273590 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and cyclosporine A (CYA)
Number of subjects: 40
Study 22273590 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 22273590 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP positive RA patients (n=18)
Number of subjects: 40
Study 20851055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT), delivered via Internet or telephone, 8 sessions over 8 weeks
Number of subjects: 40
Study 20851055 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 40
Study 16884844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 20
Study 16884844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16251607 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-rich diet (38% fat, 20% SFA)
Number of subjects: 43
Study 16251607 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (38% fat, 22% MUFA)
Number of subjects: 43
Study 16251607 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-rich diet (30% fat, 55% CHO)
Number of subjects: 43
Study 12408254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 175
Study 12408254 — intervention group
Group type: COMPARATOR
Intervention: Control (carotid sinus massage)
Number of subjects: 175
Study 10584723 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 150
Study 10584723 — intervention group
Group type: COMPARATOR
Intervention: Incremental Sevoflurane
Number of subjects: 150
Study 10584723 — intervention group
Group type: COMPARATOR
Intervention: 8% Sevoflurane
Number of subjects: 150
Study 8664221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (5 mg/100 g)
Number of subjects: 47
Study 8664221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 8664221 — intervention group
Group type: COMPARATOR
Intervention: Testosterone
Number of subjects: 47
Study 8664221 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 47
Study 2190974 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam/metronidazole
Number of subjects: 154
Study 2190974 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime/metronidazole
Number of subjects: 154
Study 30355509 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened Dental Arch (SDA)
Number of subjects: 150
Study 30355509 — intervention group
Group type: COMPARATOR
Intervention: Partial Removable Dental Prostheses (PRDP)
Number of subjects: 150
Study 30428039 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxylated phosphatidylcholine (HPC) cluster
Number of subjects: 787
Study 30428039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster including diglycerides and a monoglyceride with stearic acyl chain
Number of subjects: 787
Study 30428039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster that included highly unsaturated phospholipids and cholesterol esters
Number of subjects: 787
Study 26920606 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol therapy
Number of subjects: 514
Study 26920606 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy alone
Number of subjects: 514
Study 24867575 — intervention group
Group type: COMPARATOR
Intervention: Dehydration-Placebo (DP)
Number of subjects: 14
Study 24867575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration-Alcohol (DA)
Number of subjects: 14
Study 24867575 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Rehydration-Alcohol (PA)
Number of subjects: 14
Study 24867575 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Rehydration-Alcohol (FA)
Number of subjects: 14
Study 24867575 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (all trials)
Number of subjects: 14
Study 22092541 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 0
Study 22092541 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise training (A + R)
Number of subjects: 0
Study 20171665 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (35 mg daily for 20 weeks)
Number of subjects: 52
Study 20171665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 16814823 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tafenoquine (400mg daily x 3 days)
Number of subjects: 149
Study 16814823 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose tafenoquine (200 mg twice daily x 3 days)
Number of subjects: 149
Study 15823102 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 60
Study 15823102 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery followed by platinum-based chemotherapy
Number of subjects: 60
Study 12470183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg per day
Number of subjects: 404
Study 12470183 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg per day
Number of subjects: 404
Study 12470183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 9615912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (Pravachol), 20 mg twice daily for 12, 24, 48 and 72 hours preoperatively
Number of subjects: 36
Study 7653451 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol
Number of subjects: 61
Study 7653451 — intervention group
Group type: COMPARATOR
Intervention: quinidine
Number of subjects: 61
Study 2712985 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient physiotherapy
Number of subjects: 104
Study 2712985 — intervention group
Group type: EXPERIMENTAL
Intervention: Home mobilization advice by a physiotherapist
Number of subjects: 104
Study 2712985 — intervention group
Group type: COMPARATOR
Intervention: Analgesia and cervical collar (Control)
Number of subjects: 104
Study 728321 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg
Number of subjects: 40
Study 728321 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 1000 mg
Number of subjects: 40
Study 728321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30259621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) plus Pioglitazone (30 mg)
Number of subjects: 28
Study 30259621 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin (10 mg) alone
Number of subjects: 28
Study 28796547 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior lamina approach
Number of subjects: 211
Study 28796547 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bevel tip orientation
Number of subjects: 211
Study 28796547 — intervention group
Group type: COMPARATOR
Intervention: Inferior lamina approach
Number of subjects: 211
Study 28796547 — intervention group
Group type: COMPARATOR
Intervention: Cranial bevel tip orientation
Number of subjects: 211
Study 25795524 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect Labeling during exposure therapy
Number of subjects: 0
Study 25795524 — intervention group
Group type: COMPARATOR
Intervention: Control (exposure without affect labeling)
Number of subjects: 0
Study 23986524 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training group (PG)
Number of subjects: 36
Study 23986524 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-based resistance-training group (RG)
Number of subjects: 36
Study 23986524 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study 21121960 — intervention group
Group type: EXPERIMENTAL
Intervention: SLA implants
Number of subjects: 20
Study 21121960 — intervention group
Group type: EXPERIMENTAL
Intervention: modSLA implants
Number of subjects: 20
Study 18786258 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (1.0, 4.0, 10, and 20 mg/kg)
Number of subjects: 70
Study 18786258 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (two doses)
Number of subjects: 70
Study 18786258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16005853 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood obtained from women after vaginal delivery
Number of subjects: 0
Study 16005853 — intervention group
Group type: COMPARATOR
Intervention: Age- and gender-matched controls
Number of subjects: 0
Study 11799651 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet, therapist‐led (I)
Number of subjects: 0
Study 11799651 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐person, therapist‐led (TL)
Number of subjects: 0
Study 11799651 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 10369424 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg three times/day preprandially, adjusted to 1, 2 or 4 mg)
Number of subjects: 576